Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori

被引:6
作者
Bardhan, KD
Morton, D
Perry, MJ
Sanders, DS
Morris, P
Rowland, A
Thompson, M
Mitchell, TR
Roberts, PM
机构
[1] Rotherham Dist Gen Hosp NHS Trust, Rotherham S60 2UD, S Yorkshire, England
[2] Glaxo Wellcome R&D, Greenford, Middx, England
关键词
D O I
10.1046/j.1365-2036.2001.01040.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Both triple therapy with ranitidine bismuth citrate (RBC) plus two antibiotics for 7 days and dual therapy of RBC with clarithromycin for 14 days have been extensively studied; both regimens effectively eradicate Helicobacter pylori. However, few studies have assessed the efficacy of dual therapy given for 7 days. Aim: To compare the efficacy and safety of RBC 400 mg with clarithromycin 500 mg, alone or with metronidazole 400 mg, given twice daily for 7 days for the eradication of H. pylori. Methods: This single centre, randomized, double-blind study involved 118 patients with dyspepsia or a history of peptic ulcer disease. H. pylori infection was detected initially by CLO test, and confirmed in 109 patients by urea breath test and/or microbiology culture. H. pylori eradication was assessed 4 and 12 weeks after the end of treatment by urea breath test. H. pylori antibiotic susceptibility was assessed pre-study in all patients, and post-treatment in patients with a positive post-treatment urea breath test. Adverse events were recorded throughout the study. Results: H. pylori was eradicated in 93% of patients who received RBC with clarithromycin and metronidazole and in 84% of patients who received RBC with clarithromycin (intention-to-treat rates). Per protocol eradication rates were 98% and 90% for triple therapy and dual therapy, respectively. The eradication of metronidazole-resistant H. pylori was achieved in 100% and 88% of patients following dual therapy and triple therapy, respectively, and acquired resistance to clarithromycin occurred in only one patient following treatment failure. Both treatments were well-tolerated; only one patient (2%) was withdrawn from each treatment group due to adverse events. Conclusions: RBC with clarithromycin and metronidazole is a highly effective and well-tolerated triple therapy regimen for the eradication of H. pylori. RBC with clarithromycin dual therapy has a similar efficacy, and offers an alternative to triple therapy when there are concerns about treatment with metronidazole or the use of multiple antibiotics. Both regimens are effective against antibiotic-resistant strains of H. pylori.
引用
收藏
页码:1199 / 1204
页数:6
相关论文
共 18 条
[1]  
Bardhan KD, 1998, AM J GASTROENTEROL, V93, P380, DOI 10.1111/j.1572-0241.1998.00380.x
[2]  
Duggan A, 1998, GUT, V42, P596
[3]  
Gasbarrini G, 1998, ITAL J GASTROENTEROL, V30, P114
[4]   Report of the 1997 Asia Pacific Consensus Conference on the Management of Helicobacter pylori Infection [J].
Lam, SJ ;
Talley, NJ .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (01) :1-12
[5]   Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines [J].
Lee, J ;
OMorain, C .
GASTROENTEROLOGY, 1997, 113 (06) :S99-S106
[6]  
LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915
[7]  
Malfertheiner P, 1997, GUT, V41, P8
[8]  
Malfertheiner P, 1998, GUT, V42, P597
[9]   Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo [J].
Mégraud, F ;
Roberts, P ;
Williamson, R .
HELICOBACTER, 2000, 5 (04) :222-226
[10]  
Morton D, 1998, GASTROENTEROLOGY, V114, pA235